NASDAQ:INDP Indaptus Therapeutics (INDP) Stock Price, News & Analysis $1.45 0.00 (0.00%) (As of 09/10/2024 ET) Add Compare Share Share Today's Range$1.44▼$1.5250-Day Range$1.43▼$2.2552-Week Range$1.20▼$4.08Volume9,206 shsAverage Volume42,024 shsMarket Capitalization$12.38 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Indaptus Therapeutics alerts: Email Address Indaptus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside727.6% Upside$12.00 Price TargetShort InterestHealthy0.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.72) to ($1.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.39 out of 5 starsMedical Sector457th out of 900 stocksPharmaceutical Preparations Industry205th out of 416 stocks 3.5 Analyst's Opinion Consensus RatingIndaptus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndaptus Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Indaptus Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.10% of the float of Indaptus Therapeutics has been sold short.Short Interest Ratio / Days to CoverIndaptus Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indaptus Therapeutics has recently decreased by 12.35%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIndaptus Therapeutics does not currently pay a dividend.Dividend GrowthIndaptus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INDP. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Indaptus Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for INDP on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indaptus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders29.50% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.06% of the stock of Indaptus Therapeutics is held by institutions.Read more about Indaptus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Indaptus Therapeutics are expected to grow in the coming year, from ($1.72) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indaptus Therapeutics is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Indaptus Therapeutics is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIndaptus Therapeutics has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Indaptus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchExpert Who Predicted Lehman Collapse Issues Major New WarningHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart midflight and catching fire. But, according to analyst Dan Ferris, there's something much darker going on here that could threaten Nvidia, the Magnificent 7, and the entire U.S. stock market.Click here for the full story. About Indaptus Therapeutics Stock (NASDAQ:INDP)Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Read More INDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INDP Stock News HeadlinesSeptember 4, 2024 | finance.yahoo.comIndaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 12, 2024 | markets.businessinsider.comIndaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateSeptember 11, 2024 | Monument Traders Alliance (Ad)Join Training: Target 1,000% with One $0.99 election tradeMillionaire Trader Nate Bear is hosting a FREE TRAINING TODAY, where he'll demonstrate how his unique trading strategy can help smart Americans are using to target massive trading profits during the 2024 elections. This is the same trader who famously turned $37k into $2.7 million in just four years, right from his Georgia home.August 11, 2024 | finance.yahoo.comInsider Buyers Lose US$41k As Indaptus Therapeutics Sheds US$1.2mAugust 8, 2024 | markets.businessinsider.comIndaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private PlacementAugust 8, 2024 | msn.comIndaptus stock dips on $3M securities offeringMay 29, 2024 | finance.yahoo.comIndaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual MeetingMay 22, 2024 | finance.yahoo.comIndaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid TumorsSeptember 11, 2024 | Monument Traders Alliance (Ad)Join Training: Target 1,000% with One $0.99 election tradeMillionaire Trader Nate Bear is hosting a FREE TRAINING TODAY, where he'll demonstrate how his unique trading strategy can help smart Americans are using to target massive trading profits during the 2024 elections. This is the same trader who famously turned $37k into $2.7 million in just four years, right from his Georgia home.May 8, 2024 | investorplace.comINDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024May 8, 2024 | globenewswire.comIndaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Indaptus Therapeutics Amidst Promising Clinical Advances and Potential Market ImpactApril 12, 2024 | investing.comIndaptus reveals immune-boosting cancer therapy dataApril 12, 2024 | markets.businessinsider.comBuy Rating for Indaptus Therapeutics: Promising Oncology Breakthrough with Decoy20 PlatformApril 11, 2024 | globenewswire.comIndaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual MeetingMarch 28, 2024 | msn.comArmaguard rebuffs $26m cash lifelineMarch 28, 2024 | finance.yahoo.comIndaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 25, 2024 | globenewswire.comIndaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual MeetingSee More Headlines Receive INDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/10/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INDP CUSIPN/A CIK1857044 Webintecpharma.com Phone(646) 427-2727Fax972-2586-9176Employees6Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+727.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-146.70% Return on Assets-121.62% Debt Debt-to-Equity RatioN/A Current Ratio3.88 Quick Ratio3.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.44 per share Price / Book1.01Miscellaneous Outstanding Shares10,200,000Free Float6,020,000Market Cap$14.79 million OptionableNot Optionable Beta1.48 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Jeffrey A. Meckler (Age 57)CEO & Director Comp: $867.03kDr. Michael J. Newman Ph.D. (Age 68)Founder, Chief Scientific Officer & Director Comp: $659.99kMr. Walt Addison Linscott Esq. (Age 63)Chief Operating Officer Comp: $716.35kMr. Nir Sassi (Age 48)CFO, Secretary & Treasurer Comp: $378.47kDr. Roger J. Waltzman M.B.A. (Age 56)M.D., Chief Medical Officer Key CompetitorsCalidi BiotherapeuticsNYSE:CLDIKronos BioNASDAQ:KRONIO BiotechNASDAQ:IOBTCelularityNASDAQ:CELUCEL-SCINYSE:CVMView All Competitors INDP Stock Analysis - Frequently Asked Questions How have INDP shares performed this year? Indaptus Therapeutics' stock was trading at $1.76 on January 1st, 2024. Since then, INDP shares have decreased by 17.6% and is now trading at $1.45. View the best growth stocks for 2024 here. How were Indaptus Therapeutics' earnings last quarter? Indaptus Therapeutics, Inc. (NASDAQ:INDP) posted its earnings results on Monday, August, 12th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.07. How do I buy shares of Indaptus Therapeutics? Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INDP) was last updated on 9/11/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredFREE TRAINING TODAY ➡️ How to profit from 2024 electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands o...Monument Traders Alliance | SponsoredHow to grow a small trading account into a $100k? Why is Warren Buffett dumping stocks? Billionaires like Warren Buffett, Tim Cook, and Jeff Bezos are offloa...Timothy Sykes | SponsoredWarning For Nvidia HoldersHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart mi...Stansberry Research | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThis technology could swing the electionHidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening rig...Porter & Company | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
